Mortality predictors of Staphylococcus aureus bacteremia: a prospective multicenter study

Table 4 Comparison of survivor and fatal patients with Staphylococcus aureus bacteremia in regards to empirical antibiotic treatments and modifications (60-day mortality) (N = 255)

Variable	Fatal (N = 52)	Survivor (N = 203)	Relative risk	[95 % CI]	p value
Empirical treatment options
Peptide antibiotics	22 (42.3)	69 (33.9)	1.32	[0.81–2.15]	0.264
BL/BLI	10 (19.2)	66 (32.5)	0.56	[0.29–1.06]	0.062
BL	9 (17.3)	31 (15.3)	1.13	[0.59–2.12]	0.719
Linezolid	5 (9.6)	6 (3.0)	2.36	[1.18–4.74]	0.05
Others^a	6 (11.5)	31 (15.3)	1.1	[0.91–1.24]	0.495
Antibiotic modifications
De-escalated	3 (5.9)	17 (8.4)	0.67	[0.26–2.19]	0.773
Escalated	19 (36.5)	27 (13.3)	2.61	[1.64–4.17]	<0.0001
Unchanged	30 (57.6)	159 (78.3)	0.48	[0.29–0.76]	0.0024

Peptide antibiotics: vancomycin, teicoplanin, and daptomycin
BL/BLI beta lactam/beta lactamase inhibitors, BL beta lactam antibiotics, CI confidence interval
Data are presented as n (%). Significant p values are presented as italics (p < 0.05)
^aFluoroquinolone (ciprofloxacin, levofloxacin, moxifloxacin), 16; Tigecycline, 10; Colistin, 10

ISSN: 1476-0711